Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROBiTS trial of bi-weekly trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil alone in chemorefractory metastatic colorectal cancer
jRCTs031210544Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing FTD/TPI monotherapy with Bi-weekly FTD/TPI + bevacizumab (2 arms). Primary endpoint: Overall survival. Started Jan 2022; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031210544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210544.